A new comprehensive review from researchers at the Icahn School of Medicine at Mount Sinai details how decades of cancer vaccine research are converging into a new era of more precise, personalized, and effective immunotherapies, particularly when combined with other cancer treatments.

Researchers at Moffitt Cancer Center have developed a new way to predict how cancer cells evolve by gaining and losing whole chromosomes, changes that help tumors grow, adapt and resist treatment. In a study published in Nature Communications, scientists describe a computational approach called ALFA-K that uses longitudinal, single-cell data to reconstruct how cancer cells move through different chromosome states over time and identify which configurations are favored by evolution.

Cancer vaccine may offer new prevention strategy for patients with Lynch syndrome

Novel immunotherapy overcomes treatment resistance in multiple types of cancer

Engineered nanobodies improve respiratory defenses against multiple viruses

New combination treatments show promise for patients with early-stage Hodgkin lymphoma and breast cancer

Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an unconventional approach to metastatic cancer: instead of going after cancer cells directly, it targets the cells that protect them. The study, published in the January 22 online issue of Cancer Cell, a Cell Press Journal [DOI 10.1016/j.ccell.2025.12.021], was conducted in aggressive preclinical models of metastatic ovarian and lung cancer. It points to a new strategy for treating advanced-stage solid tumors. In a strategy modeled after the famed Trojan horse, the treatment enters the tumors by targeting cells called macrophages that guard the cancer cells, disarms these protectors, and opens up the tumor’s gates for the immune system to enter and wipe out the cancer cells.

About The Study: Mortality has decreased for every leading cancer-related death in people younger than 50 years in the U.S. except colorectal cancer, which is now the leading cancer death in females and males combined, up from the fifth-leading cancer death in the early 1990s. Breast cancer and leukemia mortality decreased despite increasing incidence.

The gut microbiota is crucial in maintaining host health and liver function. Fecal microbiota transplantation (FMT) has shown promising potential in treating chronic liver diseases. To help clinicians quickly master and standardize the clinical application of FMT for chronic liver disease, the Liver Related Digestive Diseases Group of the Chinese Society of Hepatology of the Chinese Medical Association has developed the “Expert Consensus on the Clinical Application of FMT for Chronic Liver Disease.” This consensus addresses the key aspects of FMT, including the indications, contraindications, efficacy, safety, donor selection, transplantation routes, precautions, and the prevention and management of adverse reactions for chronic liver conditions, such as chronic hepatitis, cirrhosis, and liver cancer, thereby offering reference and guidance to clinicians implementing FMT in the treatment of chronic liver disease.